RxDoctor Payments Data

Frederick Funke, MD

Cardiovascular Disease · Ladson, SCNPI 1437357274

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 530 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,953 and has fallen 67.6% since, to $633 in 2025.

$10,567in general payments, 2019–2025

Across 530 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Boston Scientific$1K
  • Medtronic$930
  • E.r. Squibb & Sons, L.L.C.$683
  • AstraZeneca$663
  • Inari Medical, Inc.$534
  • plus $5K from 33 others
$132,639in research payments, 2019–2025

Across 8 payments — averaging $16,580 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$133K

What the payments were for

  • Food & beverage$10,533100%
  • Education$340%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,567 in reported general payments places this provider in the 80th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$404,205
Medicare patients
1,124
Services billed
4,615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban195$210,792
EntrestoSacubitril/Valsartan155$162,534
JardianceEmpagliflozin48$67,820
FarxigaDapagliflozin Propanediol19$29,536
BrilintaTicagrelor42$21,581
XareltoRivaroxaban17$20,031
Repatha SureclickEvolocumab15$11,975
Varenicline Tartrate42$6,694
Ranolazine ErRanolazine24$3,523
Metoprolol Succinate179$1,845
Rosuvastatin Calcium114$1,729
ClopidogrelClopidogrel Bisulfate139$1,438
Atorvastatin Calcium128$1,065
Flecainide Acetate31$969
Ezetimibe39$838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$283$210,792195 claims
NovartisEntresto$389$162,534155 claims
Boehringer IngelheimJardiance$465$67,82048 claims
AstraZenecaFarxiga, Brilinta$663$51,11761 claims
Johnson & JohnsonXarelto$351$20,03117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Ladson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →